Earlier, GSK And Zhifei Announced Exclusive Strategic Vaccine Partnership In China; Zhifei Will Purchase Agreed Volumes Of Shingrix With A Value To GSK Of £2.5B In Total Over The Initial Three-year Period
Portfolio Pulse from Charles Gross
GSK plc has entered into an exclusive agreement with Chongqing Zhifei Biological Products to co-promote GSK’s shingles vaccine, Shingrix, in China. The deal is worth £2.5 billion to GSK over the initial three-year period. The partnership aims to extend the availability of Shingrix and supports GSK’s goal to double global Shingrix sales to more than £4 billion by 2026. Zhifei has also granted GSK the right of first refusal for co-development and commercialisation of an RSV vaccine for older adults in China.
October 09, 2023 | 9:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's partnership with Zhifei to co-promote Shingrix in China could significantly boost its revenues, supporting its goal to double global Shingrix sales by 2026. The deal is worth £2.5 billion over the initial three-year period.
The partnership with Zhifei, the largest Chinese vaccine company by revenue, will significantly extend the availability of Shingrix in China. This could lead to increased sales and revenues for GSK, supporting its goal to double global Shingrix sales by 2026. The deal is worth £2.5 billion over the initial three-year period, which is a substantial amount and could have a positive impact on GSK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100